+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
Healthy Volunteers
ID07694843

Evaluating Pharmacokinetics and Safety of Ammoxetine Hydrochloride Tablets in Adults with Mild or Moderate Liver Impairment Compared to Normal Liver Function

Led by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Updated on 2026-07-10

24

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the pharmacokinetic characteristics and safety of ammoxetine hydrochloride enteric-coated tablets in adults with mild or moderate liver impairment and those with normal liver function. This Phase I, multi-center, non-randomized, open-label trial compares participants with mild hepatic impairment Child-Pugh Class A, moderate hepatic impairment Child-Pugh Class B, and matched healthy individuals. The study aims to understand how liver function affects the drugs behavior and safety profile. Participants receive 20 mg of ammoxetine hydrochloride enteric-coated tablets orally once daily, one hour after meals, from day 1 through day 6. Three groups are studied mild hepatic impairment, moderate hepatic impairment, and normal liver function, matched by age, weight, and gender. Blood samples are collected before and after dosing to analyze pharmacokinetics and monitor safety parameters according to the trial protocol. Throughout the study, participants undergo assessments including blood sampling for drug concentration and safety evaluations. Key measures include the area under the concentration-time curve and maximum drug concentration during steady-state dosing. Safety is monitored through adverse event tracking up to 120 hours after the last dose. Participants adherence and health status are closely observed during the treatment period and follow-up, with the total participation lasting approximately one week.

CONDITIONS

Brief Title

A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and Normal Liver Function

Research Team

C

Clinical Trials Information Group officer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here